Aura Biosciences, Inc. Interest Income (Expense), after Provision for Loan Loss
Aura Biosciences, Inc. (AURA) reported Interest Income (Expense), after Provision for Loan Loss of $2.31 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Other Income
us-gaap:InterestIncomeExpenseAfterProvisionForLoanLoss · last filed 2026-08-11
- Aura Biosciences, Inc. interest income (expense), after provision for loan loss for the quarter ending 2026-06-30 was $2.31M, a 37.49% increase year-over-year.
- Aura Biosciences, Inc. interest income (expense), after provision for loan loss for the quarter ending 2026-03-31 was $1.19M, a 25.35% decline year-over-year.
- Aura Biosciences, Inc. interest income (expense), after provision for loan loss for the quarter ending 2025-12-31 was $1.54M, a 24.09% decline year-over-year.
- Aura Biosciences, Inc. interest income (expense), after provision for loan loss for the quarter ending 2025-09-30 was $1.81M, a 19.62% decline year-over-year.
- Aura Biosciences, Inc. interest income (expense), after provision for loan loss for fiscal 2025 was $6.63M, a 29.67% decline from fiscal 2024.
- Aura Biosciences, Inc. interest income (expense), after provision for loan loss for fiscal 2024 was $9.43M, a 9.79% increase from fiscal 2023.
- Aura Biosciences, Inc. interest income (expense), after provision for loan loss for fiscal 2023 was $8.59M, a 360.73% increase from fiscal 2022.
- Aura Biosciences, Inc. interest income (expense), after provision for loan loss for fiscal 2022 was $1.86M, a 14238.46% increase from fiscal 2021.
| Period end | Interest Income (Expense), after Provision for Loan Loss 3 month | Interest Income (Expense), after Provision for Loan Loss 6 month | Interest Income (Expense), after Provision for Loan Loss 9 month | Interest Income (Expense), after Provision for Loan Loss 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.31M 10-Q · filed 2026-08-11 | $3.50M 10-Q · filed 2026-08-11 | $5.04M derived: sum of 3 quarters · filed 2026-08-11 | $6.86M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $1.19M 10-Q · filed 2026-05-11 | $2.73M derived: sum of 2 quarters · filed 2026-05-11 | $4.55M derived: sum of 3 quarters · filed 2026-05-11 | $6.23M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $1.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $3.36M derived: sum of 2 quarters · filed 2026-03-30 | $5.04M derived: sum of 3 quarters · filed 2026-08-11 | $6.63M 10-K · filed 2026-03-30 |
| 2025-09-30 | $1.81M 10-Q · filed 2025-11-13 | $3.49M derived: sum of 2 quarters · filed 2026-08-11 | $5.09M 10-Q · filed 2025-11-13 | $7.12M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $1.68M 10-Q · filed 2026-08-11 | $3.27M 10-Q · filed 2026-08-11 | $5.31M derived: sum of 3 quarters · filed 2026-08-11 | $7.56M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $1.59M 10-Q · filed 2026-05-11 | $3.63M derived: sum of 2 quarters · filed 2026-05-11 | $5.89M derived: sum of 3 quarters · filed 2026-05-11 | $8.34M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $2.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $4.29M derived: sum of 2 quarters · filed 2026-03-30 | $6.74M derived: sum of 3 quarters · filed 2026-03-30 | $9.43M 10-K · filed 2026-03-30 |
| 2024-09-30 | $2.26M 10-Q · filed 2025-11-13 | $4.71M derived: sum of 2 quarters · filed 2025-11-13 | $7.39M 10-Q · filed 2025-11-13 | $10.00M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $2.45M 10-Q · filed 2025-08-13 | $5.14M 10-Q · filed 2025-08-13 | $7.74M derived: sum of 3 quarters · filed 2025-08-13 | $9.72M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $2.69M 10-Q · filed 2025-05-15 | $5.29M derived: sum of 2 quarters · filed 2025-05-15 | $7.27M derived: sum of 3 quarters · filed 2025-05-15 | $9.28M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $2.61M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $4.59M derived: sum of 2 quarters · filed 2025-03-24 | $6.60M derived: sum of 3 quarters · filed 2025-03-24 | $8.59M 10-K · filed 2025-03-24 |
| 2023-09-30 | $1.98M 10-Q · filed 2024-11-12 | $3.99M derived: sum of 2 quarters · filed 2024-11-12 | $5.98M 10-Q · filed 2024-11-12 | $7.04M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $2.01M 10-Q · filed 2024-08-08 | $4.00M 10-Q · filed 2024-08-08 | $5.06M derived: sum of 3 quarters · filed 2024-08-08 | $5.54M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $1.99M 10-Q · filed 2024-05-09 | $3.05M derived: sum of 2 quarters · filed 2024-05-09 | $3.54M derived: sum of 3 quarters · filed 2024-05-09 | $3.83M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $1.06M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $1.54M derived: sum of 2 quarters · filed 2024-03-27 | $1.84M derived: sum of 3 quarters · filed 2024-03-27 | $1.86M 10-K · filed 2024-03-27 |
| 2022-09-30 | $483.00K 10-Q · filed 2023-11-09 | $775.00K derived: sum of 2 quarters · filed 2023-11-09 | $802.00K 10-Q · filed 2023-11-09 | $805.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $292.00K 10-Q · filed 2023-08-09 | $319.00K 10-Q · filed 2023-08-09 | $322.00K derived: sum of 3 quarters · filed 2023-08-09 | $327.00K derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $25.00K 10-Q · filed 2023-05-11 | $30.00K derived: sum of 2 quarters · filed 2023-05-11 | $35.00K derived: sum of 3 quarters · filed 2023-05-11 | $39.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $5.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $10.00K derived: sum of 2 quarters · filed 2023-03-15 | $14.00K derived: sum of 3 quarters · filed 2023-03-15 | $13.00K 10-K · filed 2023-03-15 |
| 2021-09-30 | $5.00K 10-Q · filed 2022-11-10 | $9.00K derived: sum of 2 quarters · filed 2022-11-10 | $8.00K 10-Q · filed 2022-11-10 | $7.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $4.00K 10-Q · filed 2022-08-11 | $3.00K 10-Q · filed 2022-08-11 | $2.00K derived: sum of 3 quarters · filed 2022-08-11 | |
| 2021-03-31 | -$1.00K 10-Q · filed 2022-05-12 | -$2.00K derived: sum of 2 quarters · filed 2022-05-12 | ||
| 2020-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23 | -$3.00K 10-K · filed 2022-03-23 | ||
| 2020-09-30 | -$2.00K 10-Q · filed 2021-11-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |